Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDMI for Head and Neck Cancer
NCT05945875Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2023
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 111In-panitumumab and panitumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Number of grade 2 or higher adverse events at Day 15. Started Oct 2023; status: recruiting.
02
Drugs
111In-panitumumabpanitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05945875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945875.